Micafungin Pharmazac

Micafungin, the active ingredient in Micafungin Pharmazac, is an echinocandin presented as an injectable solution for intravenous use. It treats invasive candidiasis, esophageal candidiasis, and is used for prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.

GNH USA supplies Micafungin Pharmazac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Micafungin is an echinocandin antifungal that disrupts fungal cell wall synthesis, providing treatment and prevention across several Candida‑related conditions. - Invasive candidiasis: effective treatment of bloodstream and deep‑tissue Candida infections. - Esophageal candidiasis: resolves mucosal infection of the esophagus caused by Candida species. - Prophylaxis of Candida infections in hematopoietic stem cell transplantation: prevents invasive candidiasis in transplant recipients.

Micafungin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fever: transient temperature rise during or after infusion. - Nausea: mild gastrointestinal upset. - Vomiting: occasional emesis. - Headache: mild to moderate intensity. - Infusion‑related reactions: flushing, erythema, or mild hypotension. - Elevated liver enzymes: transient increase in ALT/AST.

Serious or Rare Side Effects: - Severe hepatic dysfunction: marked elevation of liver enzymes or hepatitis. - Anaphylaxis: acute, potentially life‑threatening hypersensitivity reaction. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Renal impairment: acute kidney injury in susceptible patients. - Neutropenia: significant reduction in neutrophil count. - Hypotension: marked drop in blood pressure requiring intervention.

When using Micafungin Pharmazac, clinicians should observe several safety measures. - Hepatic monitoring: assess liver function tests before and during therapy. - Renal monitoring: evaluate renal function, especially in patients with pre‑existing impairment. - Hypersensitivity: avoid in individuals with known allergy to micafungin or other echinocandins. - Severe liver disease: use with caution or consider alternative therapy. - Pediatric use: dosing and safety data are limited; follow specialist guidance. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong enzyme inducers (e.g., rifampin, carbamazepine): may markedly lower micafungin exposure. - Concurrent use with other echinocandins: no additive benefit and increased risk of toxicity. - Hepatotoxic agents (e.g., high‑dose azoles): may amplify liver injury risk.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): monitor liver enzymes for additive hepatotoxicity. - Immunosuppressants (e.g., tacrolimus, cyclosporine): observe drug levels for possible alterations. - Anticoagulants (e.g., warfarin): check INR regularly as micafungin may affect coagulation parameters.